ATCC® CRL-1619IG-1 ™ contains a heterozygous knock-in mutation in KRAS at position c.38G>A, p.G13D generated from the parental A-375 [A375] (ATCC® CRL-1619™) cells. The mutant isogenic line was generated using the CRISPR/Cas9 gene editing system followed by single cell isolation and validation. The A375 melanoma cell line is known to also contain the BRAFV600E mutation which shows sensitivity to BRAF-specific inhibitors.
|Date Created||09/28/2017 03:37 PM
|Date Updated||09/28/2017 03:37 PM